---
title: The microbial metabolite desaminotyrosine enhances T-cell priming and cancer
  immunotherapy with immune checkpoint inhibitors
date: '2023-10-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37865045/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231022180745&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'BACKGROUND: Inter-individual differences in response to immune checkpoint
  inhibitors (ICI) remain a major challenge in cancer treatment. The composition of
  the gut microbiome has been associated with differential ICI outcome, but the underlying
  molecular mechanisms remain unclear, and therapeutic modulation ...'
disable_comments: true
---
BACKGROUND: Inter-individual differences in response to immune checkpoint inhibitors (ICI) remain a major challenge in cancer treatment. The composition of the gut microbiome has been associated with differential ICI outcome, but the underlying molecular mechanisms remain unclear, and therapeutic modulation ...